SCHEMBL3767733

SCHEMBL3767733

O=C(CN1CCN(c2ccc(-c3ccc4c(c3)OCO4)nn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 6/20 0.39
LMNA P02545 5/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CHRM2 P08172 1/20 0.38
CCR5 P51681 1/20 0.38
CHRM4 P08173 4/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 3/20 0.37
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SCD5 Q86SK9 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3776361 0.95 ALDH1A1 (0.39) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL3767930 0.87 KMT2A (0.44) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL3763255 0.85 HRH3 (0.43) KMT2ALMNAHRH3NPC1MAPT
SCHEMBL3771420 0.85 HRH3 (0.41) HRH3NPC1RAB9A
SCHEMBL3767885 0.85 HRH3 (0.43) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL3774194 0.84 ALDH1A1 (0.44) ALDH1A1LMNATSHRSMN1; SMN2HRH3
SCHEMBL3767918 0.83 HRH3 (0.47) KMT2AMEN1TSHRSMN1; SMN2HRH3
SCHEMBL3767633 0.83 HRH3 (0.46) KMT2AALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL3767453 0.83 HRH3 (0.45) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL3772160 0.83 KMT2A (0.49) KMT2AMEN1ALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885MEN1 3270/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.